NRSN
NeuroSense Therapeutics Ltd.
There isn't enough reported data to score NRSN yet.
NRSN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
NRSN's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
NRSN PE Valuation
NRSN has no meaningful PE right now: it lost money over the past year.
NRSN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect NRSN's losses to shrink, with revenue growing.
NRSN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | -$8.91 | +$2.90 |
NRSN is still losing money, but less than at its worst: $8.91 per share over the past year, against $11.81 at its worst in late 2024.
NRSN Quarterly Revenue
NRSN's revenue is shrinking: $0 last quarter.
NRSN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$1.8M | -$1.8M |
| Q3 2025 | -$1.8M | -$1.8M |
| Q2 2025 | -$2K | -$2K |
| Q1 2025 | $0 | $0 |
| Q4 2024 | $0 | $0 |
| Q3 2024 | $0 | $0 |
| Q2 2024 | $0 | $0 |
| Q1 2024 | $0 | $0 |
NRSN's free cash flow was −$4M over the past year, against $0 the year before.
NRSN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | +18% | +195K shares |
NRSN has 1M diluted shares, up 18% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
NRSN hasn't bought back shares in the past year.
NRSN Net Leverage
NRSN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NRSN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 25.5 | Oversold |
| Stochastic | 4.1 | Oversold |
NRSN's weekly RSI is 26 (oversold) and its Stochastic is 4 (oversold).
NRSN PE vs Healthcare Sector
NRSN has no meaningful PE right now: it lost money over the past year.
NRSN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.19 | 45% below |
| 20 week MA | $7.39 | 76% below |
| 50 week MA | $13.2 | 87% below |
| 100 week MA | $19.6 | 91% below |
| 200 week MA | $22.1 | 92% below |
NRSN is in a downtrend: it's below all five of its weekly moving averages, and 92% below its 200-week average.
NRSN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $64.2 | $58.8 | -8.4% |
| 2022 | $58.8 | $26.0 | -56% |
| 2023 | $26.0 | $15.7 | -40% |
| 2024 | $15.7 | $25.6 | +63% |
| 2025 | $25.6 | $16.0 | -38% |
| 2026 YTD | $16.0 | $1.76 | -89% |
NRSN has finished lower in four of the last five years. It's down 89% so far in 2026.